STOCK TITAN
  1. Home
  2. News
  3. ADVM

Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 1:00 pm PT.

A live webcast will be accessible under Events and Presentations in the Investors section of the company’s website. The archived webcast will be available on the Adverum website following the presentation for 30 days.

About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.

Investor and Media Inquiries:

Investors:
Myesha Lacy
Adverum Biotechnologies, Inc.
mlacy@adverum.com
1-650-304-3892

Media:
Cherilyn Cecchini, M.D.
LifeSci Communications
ccecchini@lifescicomms.com
1-646-876-5196

 


Stock ADVM logo
Adverum Biotechnologies, Inc.

NASDAQ:ADVM

ADVM Rankings

#3954 Ranked by Market Cap
#1276 Ranked by Stock Gains
N/A Ranked by Dividends

ADVM Latest News

May 9, 2024
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
May 3, 2024
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
Apr 25, 2024
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
Mar 18, 2024
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Feb 28, 2024
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference

ADVM Stock Data

163.98M
11.72M
0.91%
80.01%
4.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About ADVM

adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.